The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Amgen Inc

Nasdaq: AMGN
Last

(U.S.) $168.68

Today's change+0.20 +0.12%
Updated December 19 10:07 AM EST. Delayed by at least 15 minutes.
 

Amgen Inc

Nasdaq: AMGN
Last

(U.S.) $168.68

Today's change+0.20 +0.12%
Updated December 19 10:07 AM EST. Delayed by at least 15 minutes.

Amgen Inc up (U.S.)$0.20

Amgen Inc is up today by (U.S.)$0.20 or 0.12% to (U.S.)$168.68. Over the last five days, shares have gained 2.52% and are currently 2.58% off of the 52-week high. Shares have outperformed the S&P 500 by 35.47% during the last year.

Key company metrics

  • Open(U.S.) $168.91
  • Previous close(U.S.) $168.48
  • High(U.S.) $170.00
  • Low(U.S.) $167.40
  • Bid / Ask(U.S.) $168.71 / (U.S.) $168.79
  • YTD % change+47.86%
  • Volume2,034,481
  • Average volume (10-day)3,728,707
  • Average volume (1-month)3,174,433
  • Average volume (3-month)4,027,176
  • 52-week range(U.S.) $108.20 to (U.S.) $173.14
  • Beta0.52
  • Trailing P/E26.55×
  • P/E 1 year forward19.56×
  • Forward PEG1.76×
  • Indicated annual dividend(U.S.) $2.44
  • Dividend yield1.45%
  • Trailing EPS(U.S.) $6.35
Updated December 19 10:07 AM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+24.74%

Based on its net profit margin of 24.74%, Amgen Inc is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.54%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue5,0315,1804,5215,011
Total other revenue--------
Total revenue5,0315,1804,5215,011
Gross profit4,1624,3023,4313,982
Total cost of revenue8698781,0901,029
Total operating expense3,5653,2783,1573,824
Selling / general / administrative1,2131,1361,0231,306
Research & development1,0181,0181,0271,249
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)529226--215
Other operating expenses, total-64201725
Operating income1,4661,9021,3641,187
Interest income (expense), net non-operating-269-282-259-261
Gain (loss) on sale of assets--------
Other--------
Income before tax1,3371,7581,2041,014
Income after tax1,2441,5471,0731,021
Income tax, total93211131-7
Net income1,2441,5471,0731,021
Total adjustments to net income--------
Net income before extra. items1,2441,5471,0731,021
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items1,2441,5471,0731,021
Inc. avail. to common incl. extra. items1,2441,5471,0731,021
Diluted net income1,2441,5471,0731,021
Dilution adjustment0------
Diluted weighted average shares771768768768
Diluted EPS excluding extraordinary itemsvalue per share1.612.011.401.33
Dividends per sharevalue per share0.610.610.610.47
Diluted normalized EPSvalue per share2.252.271.401.51